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Chapter I Introduction 
Cancer is a disease that is prevalent throughout the world in all cultures.  Cancer 
is caused by improperly regulated proliferation of cells, and cancer treatment using 
chemicals that are antineoplastic agents is referred to as chemotherapy.  Vinca alkaloids, 
the main focus of this study, are a group of agents currently being utilized in 
chemotherapy.   
Vinca alkaloids are antineoplastic agents that inhibit and combat cell 
proliferation.  They disrupt mitosis, or cell division, by binding to beta-tubulin, thereby 
interrupting microtubule formation and function.  They can also inhibit angiogenesis, or 
the formation of blood vessels.  (C. W. N. Damen, Rosing, Schellens, & Beijnen, 2010) 
Members of the vinca alkaloid family include vinblastine (VBL, the subject of this 
study), vincristine (VCR), and vinorelbine (VRB).  The majority of studies in the 
literature focus on vincristine, and analytical methodologies include gas chromatography-
mass spectrometry (GC/MS) and liquid chromatography with tandem mass spectrometry 
(LC/MS/MS).  As vinca alkaloids are important chemotherapeutic compounds, it is 
necessary to develop sensitive analytical methodologies for these materials for 
researchers, physicians, and crime laboratories.   
In order for physicians to properly determine dosing regimens, it is necessary to 
understand the pharmacokinetics of the chemotherapeutic agent, or the concentration in 
the organism over the time course of treatment.  This is possible only through sensitive 
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and selective analysis of biological fluids containing the chemotherapeutic agent and 
metabolites.  As the detection methodology becomes more sensitive, the absorption, 
distribution, metabolism, and excretion of the drug becomes observable over longer 
periods of time, resulting in a more accurate prediction of the drug levels and dosing 
regimen for chemotherapeutic effect.  In this study, the focus is on detection and 
quantitation of vinblastine and its major metabolite, deacetylvinblastine, over a specific 
time course.   
Crime laboratories will find the analytical methodologies presented in this study 
valuable in postmortem cases where medical errors in vinca alkaloid administration may 
have resulted in death.  Also, even though the alkaloids are generally available by 
prescription only, it is possible for these materials to be used in poisoning.  This 
methodology will allow crime laboratories to detect vinca alkaloids in the body.   
This study was initiated to support a pharmacokinetic study and employed 
LC/MS/MS to determine vinblastine and metabolite levels, although traditionally 
chromatography methods with non-specific detectors such as fluorescence detectors 
(LC/F) have been utilized.  The LC/MS/MS method was developed, validated, and 
applied to canine plasma samples in order to begin development of a pharmacokinetic 
model of vinblastine.   
The hypothesis of this research is that a sensitive and selective LC/MS/MS 
method can be developed to quantitate vinblastine and its metabolite at concentrations 
relevant to PBPK modeling studies (lower than 1.0 ng/mL).  The following specific aims 
will be carried out in testing the hypothesis:   
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1) Develop LC/MS/MS Method 
a. Tune ion path for MS/MS detection of compounds 
b. Optimize source parameters  
c. Develop Chromatography 
2) Validate LC/MS/MS method 
a. Sensitivity 
3) Develop a sample preparation strategy to increase sensitivity 
a. LLE 
b. SPE 
4) Validate most sensitive method 
5) Apply validated method to canine plasma samples 
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Chapter II Review of Literature 
I. History of Vinca Alkaloids 
Vinca alkaloids have been used medicinally since the 1960s.  They are important 
therapeutics in the battle against a variety of cancer types including breast cancer, non-
small cell lung cancer, bladder cancer, lymphomas, and leukemia.  Many vinca alkaloids 
have been used, including vinblastine, vincristine, and vinorelbine.  (C. W. N. Damen et 
al., 2010) 
1. Vinblastine  
Vinblastine (VBL) is a natural alkaloid found in the periwinkle plant, 
Catharanthus roseus.  It is primarily eliminated from the body in its unchanged form 
along with a small amount of deacetylvinblastine, its metabolite.  (Baselt, 2008)  The 
structure of vinblastine is shown in Figure 1 and deacetylvinblastine is shown in Figure 2. 
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Figure 1.  Chemical structure of vinblastine.  
(Moffat, Osselton, Widdop, & Galichet, 2004) 
 
 
 
Figure 2.  Chemical structure of deacetylvinblastine.   
 (SciFinder, 2010) 
 
Vinblastine is administered either orally or through intravenous injection.  Over a 
six-day period, a dose of intravenous injection is eliminated through urine and feces.  The 
elimination product of unchanged vinblastine and deacetylvinblastine can be found in 
urine.  Vinblastine has a half-life of 12 to 48 hours. (Baselt, 2008) 
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The toxicity of the drug depends on the dosage and duration of use.  Side effects 
include nausea, vomiting, abdominal pain, muscle pain, headache, paresthesia (tingling, 
numbness, and pricking of the skin), malaise (discomfort), hypertension, and leucopenia 
(white blood cells reduction).  More severe side effects include seizures, coma, epidermal 
necrolysis (skin loss), inappropriate secretion of antidiuretic hormone and death. (Baselt, 
2008) 
2. Vinorelbine 
Vinorelbine (VRB) did not come into clinical use until the 1990s.  It is a semi-
synthetic derivative of vinblastine (Baselt, 2008).  Vinorelbine has many metabolites, 
including desacetylvinorelbine, vinorelbine N-oxide, and 20’-OH-vinorelbine.  The 
structure of vinorelbine is shown in Figure 3. 
 
Figure 3.  Chemical structure of vinorelbine.   
(Moffat et al., 2004) 
Vinorelbine can be absorbed rapidly when taken orally, with times ranging from 
0.75 to 3.0 hours.  It has a higher level of binding to platelets than to plasma proteins.  
One reported half-life for vinorelbine ranges from 21 to 41 hours (C. W. Damen et al., 
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2008), but other sources report the half-life of vinorelbine ranging from 20 to 80 hours 
(Baselt, 2008).   
Vinorelbine can also be taken through intravenous injection.  Over a 3-week 
period, a dose of vinorelbine is eliminated through urine and feces.  Vinorelbine, 
desacetylvinorelbine, vinorelbine-N-oxide, and 20`-OH-vinorelbine can all be found in 
urine.  (Baselt, 2008) 
Some side effects of vinorelbine include dose-limiting granulocytopenia, nausea, 
alopecia (hair loss), dyspnea (shortness of breath), paralytic ileus (intestinal blockage), 
thrombocytopenia (low platelets level in blood), peripheral neuropathy (nerve damage of 
the brain/spinal cord), fatigue, fever, tachycardia (acceleration of heart rate), myalgia, 
constipation, and hand-foot syndrome (leakage of blood causing tissues damage).  
(Baselt, 2008) 
3. Methods of detection 
a) Prior detection methods 
Prior to LC/MS, other methods for studying vinblastine were utilized.  These 
typically involved HPLC coupled with different detection methods, including 
fluorescence (Vendrig, Teeuwsen, & Holthuis, 1988) and electrochemical detection. 
(Volkov & Grodnitskaya, 1994) 
In 1988, vinblastine was studied by using an HPLC method coupled with 
fluorescence.  Before this method was developed, HPLC were performed on a reverse-
phase column.  However, this method resulted in broad and tailing peaks due to unwanted 
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peak absorption.   The method in this paper suggested the addition of an ion-pairing 
reagent to the mobile phase (acetonitrile) and silica gel as the stationary phase.  This 
alteration to the method would yield better peak shapes and a shorter retention time.  
Vinblastine in urine and plasma was explored with vindesine as the internal standard.  
Because the mobile phase had a high concentration of organic solvent, fluorescence 
detection was used.  The calibration curve ranged from 0.5-100 ng/mL.  The LOD for this 
method was 0.5 ng/mL for vinblastine with a noise-to-signal ratio of three.  DVBL was 
also explored in this method; however, the HPLC method could not detect low 
concentrations of DVBL since DVBL co-eluted with an unknown peak.  The peak was 
present in all samples and the two peaks could not be resolved.  The overall results 
showed that HPLC with ion-exchange chromatography coupled with fluorescence gave a 
lower LOD than previous HPLC method with reverse-phase chromatography coupled 
with electrochemical detection.  (Vendrig, Teeuwsen, & Holthuis, 1988) 
In 1994, another study was done with vinblastine using an HPLC method and thin 
layer chromatography (TLC).  For this experiment, the interest was not in plasma or urine 
but in the leaves of the plant C. roseus.  Previous methods used were time consuming and 
involved complicated preparation steps.  Therefore, TLC was used as a purification 
method, followed by analysis of the purified materials with HPLC.  The retention time 
for this method ranged from 20-25 minutes, it had a very high recovery rate (greater than 
96.7%), and the LOD was 2.5 µg/mL with a signal-to-noise  ratio of seven.  (Volkov & 
Grodnitskaya, 1994) 
A different method of detection of vinblastine was introduced in 1996.  
Vinblastine was extracted from C. roseus plants and analyzed by  capillary zone 
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electrophoresis (CZE) with mass spectrometry as the detection method.  In this study, 
both vinblastine and vincristine were tested, but since both compounds are similar in 
structure and pKa, this caused a great challenge for method development.  Voltage, buffer 
composition, pH and sample concentration were all explored to determine their effect on 
the compounds.  The overall results showed that 10kV, 75 µm I.D. column, buffer pH of 
6.2, 0.2 M ammonium acetate, and addition of an organic modifier gave the best limit of 
detection, resolution, and retention time.  The LOD was estimated to be 1.0 ppm (or 1000 
ng/mL).  (Chu, Bodnar, White, & Bowman, 1996) 
In 2002, another method of vinblastine analysis was developed.  The method used 
supercritical fluid extraction (SFE) and HPLC-ESI-MS.  This development is an 
alternative way of extracting vinblastine from plants without using any organic solvents. 
SFE was used to extract alkaloids from plants, which increases the solubility and 
desorption from the matrix.  HPLC-ESI-MS was used as a simple and rapid analytical 
method because it does not involve any clean-up steps that could cause the loss of the 
analytes.  For SFE, a basified supercritical carbon dioxide (CO2) was used.  The 
standards ranged from 0.4 – 30 µg/mL, and the assumption from this method was that the 
LOD was 0.4 ng/mL because no LOD or LLOQ was reported.  (Choi, Yoo, & Kim, 
2002) 
All of the methods mentioned above were presented in peer-reviewed literature, 
yet the methods were not sensitive or selective enough for use in the PBPK modeling 
application presented here.  While LC/MS results are presented above, tandem mass 
spectrometry (LC/MS/MS) can offer greater selectivity and is therefore the method of 
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choice if instrumentation is available.  Therefore, the peer-reviewed literature related to 
vinca alkaloids analysis via LC/MS/MS is presented below. 
b) LC/MS/MS methods 
Many labs have developed LC/MS or LC/MS/MS methods for vinca alkaloid 
detection over the years.  An article by Corona et al. in 2008 reported using atmospheric 
pressure chemical ionization liquid chromatography/tandem mass spectrometry (APCI-
LC/MS/MS) to detect vincristine (VCR) in human plasma with vinblastine (VBL) as an 
internal standard.  An APCI source was used in positive ion and multiple reaction 
monitoring (MRM) modes.  The parent ions [M-H]+ were 825.3 m/z and 811.3 m/z and 
daughter ions were 765.3 m/z and 751.3 m/z for VCR and VBL, respectively.  (Corona, 
Casetta, Sandron, Vaccher, & Toffoli, 2008) 
The calibrators consisted of 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, 10.0, 20.0, 50.0, 100.0, 
200.0, and 500.0 ng/mL of vincristine.  Plasma sample preparation started with mixing 
plasma with 200 µL of methanol/0.2 M ZnSO4 mixture and 20 ng/mL of VBL.  The 
samples were then vortexed for 15 seconds and centrifuged for 10 minutes at 6000xg at 
4°C.  A 200µL aliquot was transferred into a vial for injection.  The samples were passed 
through an online solid phase extraction (SPE) and liquid chromatography step before 
entering the MS/MS.   (Corona et al., 2008) 
The data underwent statistical analysis to determine the lower limit of quantitation 
(LLOQ), precision, and accuracy.   The result for the LLOQ was 0.1 ng/mL with 1.2 to 
6.8% for intra-day precision, and 3.0 to 5.1% for inter-day precision.  For accuracy, the 
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mean relative error was from 0.1 to 6.1% for intra-day and 0.01 to 3.2% for inter-day.   
(Corona et al., 2008) 
In the past three years, scientists have worked extensively with vincristine and 
vinorelbine detection using high performance liquid chromatography tandem mass 
spectrometry coupled with electrospray ionization (ESI-LC/MS/MS).  The earliest work 
was the analysis of vinorelbine in mouse and human plasma in 2008.  The optimized 
compounds have masses of 779 m/z and 122 m/z for vinorelbine, 811 m/z and 224 m/z for 
vinblastine, and 970 m/z and 355 m/z for vintriptol.  Offline SPE was used to isolate the 
drugs from plasma.  (C. W. Damen et al., 2008) 
After spiking the plasma, the samples were agitated for ~10 s and centrifuged for 
10 minutes at 10500xg.  Bond-Elut C2 cartridges were used for the extractions.  The 
extraction started with adding 1.0 mL of methanol two times and 1.0 mL of water two 
times.  A 200 µL aliquot of the sample was added to the column and washed twice with 
1.0 mL of water.  Negative pressure was applied for one minute until the column is dry.  
Analytes were eluted using 1.0 mL of methanol and evaporated under nitrogen gas at 
40°C.  The residue was resuspended using100 µL of vintripol (IS) working solution.  
After vortexing for one minute, the samples were centrifuged at 10900xg for 10 minute 
and transferred to vials.  The result LLOQ for vinorelbine in mouse plasma was 0.80 
ng/mL.  (C. W. Damen et al., 2008) 
Another article in 2009 accomplished simultaneous quantification of vincristine 
and actinomycin-D in human plasma using LC/MS/MS.  The standards in plasma were 
0.25, 1.0, 5.0, 10, 25, 50,75, and 100 ng/mL for vincristine and 0.50, 2.5, 10, 25, 50, 100, 
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150, and 250 ng/mL for actinomycin-D.  The samples were extracted from plasma using 
protein precipitation and the supernatant was transferred to a vial with inserts.  
Vinorelbine and 7-aminoactinomycin-D (7-AAD) were used as the internal standards at a 
concentration of 50 ng/mL.  The masses used for Q1 and Q3 detection were as follows: 
825 m/z and 765 m/z for vincristine, 1256 m/z and 875 m/z for actinomycin-D, 779 m/z 
and 122 m/z for vinorelbine, and 1217 m/z and 872 m/z for 7-AAD.  ESI, APCI, and 
heated ESI (H-ESI) were all tested to determine which one yielded the greatest 
sensitivity.  The results showed that H-ESI produced the highest signal-to-noise (S/N) 
ratios.  However, the precision was very poor; therefore, ESI was used for the remainder 
of the research.  7-AAD LLOQ accuracies for inter- and intra-assay met the pre-defined 
criteria; therefore vinorelbine was employed as the internal standard.  The calculated 
LLOQ for vincristine was 0.25 ng/mL and the LLOQ for actinomycin-D was 0.50 ng/mL. 
(C. W. N. Damen, Israels, et al., 2009) 
The most recent article in 2009 by this group talked about the analysis of 
vinorelbine and 4-O-deacetylvinorelbine in plasma using LC/MS/MS coupled with H-
ESI.  The calibration curve ranged from 0.10 to 100 ng/mL for both drugs.  Deuterated 
vinorelbine, or vinorelbine-d3, was the internal standard at 50 ng/mL.   The samples were 
extracted from human or mouse plasma by protein precipitation.  The precursor ions for 
the vinorelbine, 4-O-deacetylvinorelbine and vinorelbine-d3 were 779 m/z, 737 m/z and 
782 m/z, respectively.  The product ion for all three drugs was 122 m/z.  The calculated 
LLOQ for both vinorelbine and 4-O-deacetylvinorelbine was 0.10 ng/mL.  (C. W. N. 
Damen, Lagas, Rosing, Schellens, & Beijnen, 2009) 
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A study in 1997 by Ramirez, Ogan, & Ratain used APCI-LC/MS to detect 
vinblastine, deacetylvinblastine, and vincristine in human plasma.  The goal was to 
develop a method that can detect vinblastine, deacetylvinblastine, and vincristine from 
0.30 to 4.00 ng/mL.  The internal standard chosen for this study was vinorelbine.  The 
samples went through liquid-liquid extractions with chloroform as the solvent and the 
organic phase was dried all the way down under nitrogen gas.  Then, the pellet was 
resuspended in 100 µL of acetonitrile and transferred into vials. The calibration curve 
results for vinblastine ranged from 0.51 to 4.00 ng/mL, deacetylvinblastine ranged from 
0.74 to 3.93 ng/mL, and for vincristine from 0.30 to 3.95 ng/mL.  (Ramirez, Ogan, & 
Ratain, 1997) 
Zhou, Tai, Sun, & Pan’s research goal was to develop a method that could 
identify Vinca alkaloids by using direct injection ESI-MS and MS/MS, and also by ESI-
LC/MS and ESI-LC/MS/MS.  The sample preparation procedures included reverse phase 
silica gel chromatography and confirmation of compound by ultraviolet (UV), MS, and 
nuclear magnetic resonance (NMR) spectral data.  The interest of this research was to 
identify vinca alkaloids and metabolites.  Vinblastine precursor and product ions reported 
in the Zhou  paper were used to compare to the ions of interest in the present research as 
part of method development.  (Zhou, Tai, Sun, & Pan, 2005) 
In summary, all the LC/MS methods reviewed above showed that LC/MS/MS is a 
sensitive method and vinca alkaloid, specifically vincristine, was detected at 0.050 
ng/mL. The main focus of mentioned LC/MS/MS methods was on vincristine and 
vinorelbine, not vinblastine.  Literature on the quantification of vinblastine using the 
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LC/MS/MS was not found; therefore, this research will focus on developing a method to 
analyze vinblastine using the LC/MS/MS.   
II. LC/MS/MS 
Liquid chromatography tandem mass spectrometry is a newer technique that is 
becoming more commonly used in toxicology labs.  LC/MS/MS is sometimes preferred 
over gas chromatography due to its efficiency and sensitivity.  Unlike GC, samples that 
are going into the LC/MS/MS for analysis do not need to go through as much 
preparation, and compounds that are not stable in the GC/MS are more stable in the 
LC/MS/MS.  (Cody, 2006) 
1. Liquid Chromatography 
Liquid chromatography is defined as the separation of one or more compounds in 
a process involving a mobile and stationary phase.  Factors that can influence compound 
separation are temperature, column packing, column size, solvent polarity, and flow rate.  
The polarity of the mobile phase depends on the solvents or the mixture of solvents. The 
column in the LC contains porous packing that is known as the stationary phase, which 
contain either silica or alumina adsorbents.  LC has two types of separation, known as 
normal and reverse phase.  (Stafford, 2006) 
a) Normal phase chromatography 
Normal phase chromatography has a nonpolar mobile phase and polar stationary 
phase.  It is ideal to use normal phase chromatography for separation of nonpolar 
molecules. The idea of chromatography is to separate analytes of interest from other 
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molecules based on differential partitioning.  Molecules will tend to stay longer with the 
phase that has matching polarity.  As the mobile phase increase in polarity, the analytes 
tendency to stay in the stationary phase decreases.  The retention time will be shorter 
because the mobile phase will have a higher polarity, causing the analytes to elute more 
quickly.  (Stafford, 2006) 
b) Reverse phase chromatography 
Reverse phase chromatography is the opposite of normal phase.  The mobile 
phase has high polarity and the stationary phase has low polarity.  The solvents for the 
mobile phase usually consist of water and methanol, acetonitrile, or tetrahydrofuran.  
Unlike normal phase chromatography, reverse phase has better selectivity and an aqueous 
mobile phase, which is much preferred to organic solvents.  (Stafford, 2006) 
2. Mass Spectrometry 
Mass spectrometry identifies ions traveling through the mass spectrometer and is 
ideal for qualitative identification.  Samples can be introduced into the MS either by GC, 
LC, or capillary electrophoresis (CE).  Once the sample enters the mass spectrometer, it 
goes into the ion source, which will ionize the analytes.  Typically in LC/MS/MS, either 
electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI) is used.   
a) Electrospray Ionization 
ESI is the most frequently used mode of ionization in the analytical toxicology 
field.  The voltage applied determines if the nebulised droplets trapping the ionized 
analyte will be positively or negatively charged.  ESI can produce ions in two different 
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conditions, positive mode and negative mode.  Positive mode is best when working with 
basic drugs that form a stable HCl salt.  In this mode, [M+H]+ is the primary ion formed 
along with [M+nH]n+ and [M+nNa+]+.  For negative mode, it is best suited to acidic drugs 
that form stable Na salts.  Three ions are formed from negative mode, [M-H]-, [M-nH]n+, 
and [M+I-]-.  (Politi, Groppi, & Polettini, 2006) 
The process for ESI involves three major components: production of charged 
droplets, droplet reduction and fission, and gas phase ion formation.  To produce charged 
droplets, a large voltage is applied to the end of the capillary before the solvent reaches 
the MS entrance.  This voltage causes the excess charge at the tip of the capillary to 
overcome surface tension and form a droplet.  The droplets then go through desolvation 
and fission, which is caused by electric repulsion between like charges.  The final step is 
to get the droplets into the gas phase, which involves several different mechanisms that 
play a role.  (Politi, Groppi, & Polettini, 2006) 
ESI is the ideal method to use when working with large molecules like proteins 
and with compounds that are not thermally stable.  The ESI method can be used in a wide 
range of analytes, is highly efficient, and results in very little decomposition of labile 
analytes.  However, it must be used at lower flow rates (concentration dependent), the 
analyte must form solution phase ions, and ion suppression is prevalent.  (Politi, Groppi, 
& Polettini, 2006) 
b) Atmospheric Pressure Chemical Ionization 
The process for APCI is very different from ESI.  For APCI, the solvent is 
sprayed into a heated chamber by the capillary and a coaxial flow of nebulizer gas.  The 
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high temperature causes the solvent to evaporate leaving the analyte in the gas phase to 
be ionized.  A corona discharge electrode is placed near the tip of the capillary to act as a 
source of electrons.  The electrons cause the ionization of the atmosphere surrounding the 
tip, which causes the excess reagent ions and the analyte to interact.  APCI has two 
different modes, negative and positive.  Positive-ion mode occurs when the proton 
affinity of the analyte is higher than that of the reagent ions.  Negative mode is when the 
analyte donates a proton to the reagent ions.  Ionization by charge transfer can happen 
producing M+ and M- ions.  (Politi, Groppi, & Polettini, 2006) 
In cases where the polarity and molecular weight are low, APCI is the best 
method to use.  The background level for APCI is lower than ESI; however, compounds 
must be thermally stable to use this method.  Other APCI advantages also include: very 
high ionization efficiency (approaching 100%) and low susceptibility to chemical 
interferences.  (Politi, Groppi, & Polettini, 2006) 
c) Ion separation and detection 
There are several types of mass spectrometry, but in this case a quadrupole mass 
spectrometer was used.  Essentially, this acts as a mass filter and only allows ions of a 
specific mass to charge ratio to reach the detector.  If a mass spectrometer has one 
quadrupole, it is termed a single quadrupole instrument (MS).  Multiple quadrupoles 
coupled together with additional fragmentation allows for tandem mass spectrometry 
(MS/MS).  In tandem mass spectrometry, there are typically three quadrupoles that allow 
it to function: Q1, Q2, and Q3.  After ionization in the instrument source, the ions enter 
Q1 where precursor ions are selected specifically by their mass to charge ratio (m/z).  The 
18 
 
selected precursor ions would then enter the collision cell, or Q2, where they get broken 
into fragments, which are known as product ions.  The product ions then continue into Q3 
where they are specifically selected by the mass to charge ratio (m/z) for detection.  
(Politi, Groppi, & Polettini, 2006) 
III. Method Development 
To successfully develop a method, the following steps must be followed.  First, 
the problem must be identified, which includes reviewing the literature and selecting the 
analytes and internal standard.  The second step is to optimize the mass spectrometry so 
the analyte can be detected.  This includes selecting the best ionization mode (APCI or 
ESI), optimization of source parameters, and tuning the ion path.  Next, the 
chromatography is optimized.  After the LC/MS method is essentially developed, sample 
preparation, which may includes extraction processes, is optimized.  
1. Tune ion path 
To tune the ion path, samples are injected directly into the MS/MS to determine if 
the analyte of interest can be seen.  It may be necessary to vary the concentration of 
analyte being injected, as well as modify the mode of ionization, whether it be APCI or 
ESI.  Once it is certain that the analytes can be detected, source parameters are optimized.   
2. Optimize source parameters 
Like tuning the ion path, optimizing the source parameters involves direct 
infusion of the drug into the tandem mass spectrometer, without going through liquid 
chromatography.  When optimizing the source parameters, it is sometimes necessary to 
run as much solvent into the MS/MS system as would be expected when chromatography 
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is developed.  The goal of optimizing the source parameters is to increase the sensitivity 
of the analysis.  This is done through modification of source parameters including 
voltage, gas flow and temperatures.  Since ESI and APCI utilize different mechanisms of 
ionization, the optimized parameters for each mode are different.   
3. Optimize chromatography 
Once the source parameters are optimized, chromatography can be optimized.  
This involves selection for the appropriate chromatography column for separation.  
Besides selecting the correct column, flow rate and mobile phase have to be adjusted for 
optimal resolution and detection.  
4. Optimize extraction  
Optimizing extraction is part of sample preparation that involves testing many 
different solvents and methods of extraction that would yield the best recovery.  The 
objectives of an extraction are to isolate the compound of interest from any interfering 
components and to concentrate the analyte for detection.  For optimal recovery, the 
method must produce good yield of the analytes with the least sample loss, successful 
removal of other interfering components, little to no matrix effect, and the conversion of 
the analytes must be suitable to be detected.  (Taylor, 2006)  Liquid-liquid extraction 
(LLE) and solid phase extraction (SPE) will be focused on because they are the most 
common methods of extraction for vinca alkaloids.   
a) Liquid-liquid extraction 
LLE is the most commonly used method of extraction because drugs can be 
extracted directly from bodily fluids (blood, urine, etc.).  LLE involves two phases, both 
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being liquid.  To determine the best organic solvent to be used, the solvent polarity 
(solubility and dielectric constant) and hydrogen bonding ability are important factors to 
take into consideration.  The drugs are usually converted to non-ionic form with a 
buffered solution.  The non-ionic form of the drugs will partition readily in the organic 
solvent.  The drugs are divided into 6 classes: strong acids (pKa=1 to 5), weak acids 
(pKa=5 to 9), neutrals, weak bases (neutral below pH 5), bases (neutral at 7 or above), 
and amphoteric bases. The pH is usually adjusted two pH units above (2 pH below for 
amines) the pKa of the drugs to produce 100% un-ionized forms.  pH adjustment is 
important when doing back-extractions.  Other factors that are used in consideration for 
solvents selection include cost, safety, and odor.  (Siek, 2006) 
b) Solid phase extraction 
Solid phase extraction also involves two phases, but one is liquid and the other is 
solid.  Typical sorbent beds include chemical functional groups that are also common to 
chromatography systems, like silica gel.  The idea of SPE is to selectively bind drugs 
from an aqueous matrix, allow proteins, lipids and carbohydrates to pass through, and 
then allow the drugs to elute.  The major goal of the process is to highly concentrate the 
drugs without the unwanted components.  Unlike LLE where the extraction process is 
direct and quick, SPE involves more time, solvent, and materials.  The usual steps of SPE 
are: wet the column with methanol, rinse with water, load samples, wash with water, 
rinse with methanol, dry the column, and elute the drugs with an organic solvent.  (Siek, 
2006) 
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IV. Method Validation 
1. Sensitivity 
Sensitivity refers to the smallest quantity that a method can detect (limit of 
detection, LOD) and quantitate (lower limit of quantitation, LLOQ). 
a) Limit of detection 
The limit of detection (LOD) is the calculation of the lowest concentration that 
the MS can detect of the ions.  To calculate the LOD, the slope and the y-intercept of the 
line must be known.  The equation of the best-fit line can be determined by plotting the 
quantitative ratios of each run on a scattered plot graph.  The y-intercept and slope of 
each line will be used to calculate the standard deviation and mean of the slopes.  The 
standard deviation will then be used to calculate the LOD.  (ICH Harmonised Tripartite 
Guideline, Validation of Analytical Procedures: Methodology, 1996) 
Equation 1. LOD 
LOD = (3.3 * SD of the y-intercept) / mean of the slope 
(ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: 
Methodology, 1996) 
b) Lower limit of quantitation 
The lower limit of quantitation (LLOQ) is the lowest concentration of the analytes 
that the MS can accurately and precisely measure.  The calculation for LLOQ is similar 
to the LOD but it differs in the multiplication factor.  
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Equation 2. LLOQ 
LLOQ = (10 * SD of y-intercept) / mean of the slope 
(ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: 
Methodology, 1996) 
2. Precision 
Precision is the reproducibility of the same results.  It is determined by looking at 
the variability in the calibrators within a single day or between days.  To determine the 
reproducibility of the method, the same sample must be run at least three times for 
comparison.  The follow equation is used to determine the precision percentage: 
Equation 3. Precision 
% Precision = calculated concentration mean/SD of calculated concentration * 100  
(Stout, Bynum, Mitchell, Baylor, & Ropero-Miller, 2009) 
To calculate for precision, the concentration of each calibrator must be calculated 
from the standard curve.  The average of the calculated concentration from each run 
(n=3) is taken and the standard deviation for all three calculated concentrations is used to 
calculate precision.  To determine precision, the mean is divided by the standard 
deviation and multiplied by 100.  (Stout et al., 2009) 
3. Accuracy 
Accuracy is the first step in method validation.  Accuracy, also known as percent 
error, is calculated by determining the closeness between the experimental value and the 
true value.  The following equation is used to calculate accuracy: 
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Equation 4.  Accuracy 
% error = (experimental value – true value)/true value x 100 
(Stout et al., 2009) 
For the values to be accepted, the experimental value must be within 15% of the 
true value, except for LLOQ where the value must be within 20%.  (Stout et al., 2009) 
4. Selectivity 
Selectivity is used to calculate for any interference that could effect the detection 
of the analytes.  To determine the selectivity of the method, matrix effects must be 
explored. 
a) Matrix effects 
To test for matrix effects, the samples are prepared by three different methods: no 
extraction (neat solution, A), spiked plasma after extraction (B), and plasma spiked 
before extraction (C).  Matrix effect (ME) is calculated by dividing the peak area of the 
standards spiked after extraction (B) by the neat solution (A) and multiplying by 100 
(Equation 5).  The ME value takes into account any ion suppression or enhancement.  
The  recovery percentage of the extraction is calculated by dividing plasma spiked before 
extraction (C) by the standards spiked after extraction (B) and multiplying by 100 
(Equation 6).  Precision efficiency (PE) is calculated by dividing the peak area of the pre-
extraction (C) samples by neat solutions (A) and multiplying by 100 (Equation 7).  The 
three equations are used to determine if any interference was present during the 
extraction process. (Matuszewski, Constanzer, & Chavez-Eng, 2003) 
The following equations are used to determine matrix effects: 
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Equation 5.  Matrix Effect 
ME (%) = B/A x 100 
Equation 6.  Recovery Efficiency 
RE (%) = C/B x 100 
Equation 7.  Process Efficiency 
PE (%) = C/A x 100 
(Matuszewski et al., 2003) 
V. Case study 
In 2007, an article reported a medical error case that resulted in the death of a 
patient.  An 83-year-old woman died from an overdose of vinblastine due to mistakes 
made by three parties: the physician, pharmacist, and nurse.  The story started when the 
patient was in an accident, which resulted in a contusion on her lower leg.  The bruising 
of the leg continued for a long time, so she went to the doctor.  Because the patient was 
diabetic and the wound would not heal, her doctor suggested that she start on therapy 
with a new drug that he prescribed as “vinplastin.”  The drug that the physician had in 
mind was “vasolastine,” a drug that modifies vasoreactivity.   The patient’s daughter took 
the prescription to the pharmacy.  The staff at the pharmacy could not read what the 
physician wrote and assumed that the physician wrote “vinblastin,” since vinblastin and 
vinplastin are similar.  The drug was given to the nurse who administered 5 mg of 
vinblastine to the patient every day without noticing that she was giving the patient an 
anti-cancerous drug.  This caused the patient’s health to deteriorate over time.  The 
patient was admitted to the hospital after doctors realized that she was being administered 
a high dose of an anti-cancerous drug without reason.  The patient was administered 3 
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different antibiotics, a granulocyte growth-inducing agent and an anti- fungal medication.  
The medications did not help the patient and her health continued to deteriorate.  Her 
leukocytes dropped significantly and she was starting to have symptoms like bloody 
vomit, fever, pneumonia, and decrease in body pH and arterial blood pressure.  The 
patient suffered cardiac arrest, was resuscitated, but went into a coma after four days of 
treatment.  She died a few hours later.  (Klys, Konopka, Scislowski, & Kowalski, 2007) 
Postmortem examination showed that she had hemorrhage in her uterus, tubal, 
and ovary, petechiae (small red/purple spot caused by bleeding) in the intestinal mucous 
membrane and pulmonary edema (fluid in lungs).  Toxicologists used APCI-LC/MS/MS 
method to determine the concentration of vinblastine in the patient.  The analysis showed 
that the patient had 29 ng/g of vinblastine in her blood and 52.2 ng/g in the liver, which is 
much higher than what is found in a patient going through chemotherapy.  (Klys et al., 
2007)
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Chapter III Methodology 
I. Introduction 
The following vinca-alkaloid studies were first carried out in methanol and water 
for simplicity.  Once an initial method was developed, vinca alkaloids were diluted in 
plasma to create a finalized method that was optimized and validated.  As stated 
previously, the following specific aims were addressed: 
1) Develop LC/MS/MS Method 
a. Tune ion path for MS/MS detection of compounds 
b. Optimize source parameters 
c. Develop Chromatography 
2) Validate LC/MS/MS method 
a. Sensitivity 
3) Develop a sample preparation strategy to increase sensitivity 
a. LLE 
b. SPE 
4) Validate most sensitive method 
5) Apply validated method to canine plasma samples 
1. Instrument and materials 
   A Shimadzu HPLC system (Shimadzu Corporation, Kyoto, Japan) consisting of a 
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system controller (CBM-20A), solvent delivery unit (LC-20AD), an auto-sampler (SIL-
20AC) and a column oven (CTO-20AC) with a Restek Allure Pentafluorophenyl (PFP) 
Propyl 5µm 50x2.1mm column (Restek, Bellefonte, PA) was utilized.  An Applied 
Biosystems 4000 Q- Trap MS/MS System (Applied Biosystems, Foster City, CA) 
equipped with a Turbo VTM electrospray ionization source, a Harvard Apparatus syringe 
pump (Holliston, MA) and a NitroGen N300DR nitrogen generator was used (Peak 
Scientific Instruments Ltd, Paisley, United Kingdom). Analyst® 1.5 Software was used to 
control the instrument and for data analysis.  For SPE, an Oasis HLB Water 1 mL 
cartridge was used. 
 Chemicals used include: ACS grade methanol (VWR International, West Chester, 
PA) and 98% formic acid (EMD Chemicals, Gibbstown, NJ); HPLC grade acetonitrile 
(OmniSolv, EM Science, Gibbstown, NJ) and methanol (OmniSolv, EMD, Gibbstown, 
NJ); Ammonium formate, 99% (Alfa Aesar, Ward Hill, MA); Ammonium acetate crystal 
(Mallinckrodt, Phillipsburg, NJ); glacial acetic acid (EMD, Gibbstown, NJ); isopropyl 
alcohol (Mallinckrodt, Paris, KY); HPLC grade hexane (Acros, NJ); ethyl acetate (Acros, 
NJ), ethyl ether (VWR, BDH, West Chester, PA); chloroform (BDH, West Chester, PA).  
Plasma, vinblastine, deacetylvinblastine, and vinorelbine in methanol solution were 
provided by collaborators at the Oklahoma State University Center for Veterinary Health 
Sciences (OSU CVHS). 
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II. Specific Aim 1: Develop LC/MS/MS method 
1. Tuning ion path for MS/MS detection of compounds 
A mixture of all three chemicals was infused into the tandem mass spectrometry 
at a concentration of 100 ng/mL for vinblastine, vinorelbine, and deacetylvinblastine.  
The flow rate was 20 µL/min.  For this experiment, APCI-LC/MS/MS was be utilized for 
detection, based on a comparison of signal to noise ratios.  Table 1 shows the parent ions 
(Q1) and daughter ions (Q3) that the MS/MS was detecting for each compound.   
 
Table 1.  Q1 and Q3 masses for VRB, DVBL, and VBL. 
 
 
 
 
 
 
Mobile phase: 
Eluent A – (0.20% Formic, 0.20% Ammonium formate in water) 2.0 mL 1.0 M 
ammonium formate, 2.0 mL formic acid, 996 mL DI H2O 
Q1 
VRB 
(779.4 m/z) 
DVBL 
(769.4 m/z) 
VBL 
(811.5 m/z) 
Q3 
122.2 124.2 144.1 
457.2 144.1 224.1 
658.2 355.1 355.1 
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Eluent B – 2.0 mL 1.0 M-ammonium formate, 2.0 mL formic acid, 996 mL 
Acetonitrile (ACN) 
2. Optimize source parameters 
To optimize the source parameters, standards were injected directly into the MS/MS.  
Direct infusion was used to determine the optimal parameters (gas 1, gas 2, temperature, 
etc.) for detection.  Table 2 shows the parameters that were set for the method that was 
used to run the calibrators. 
Table 2.  LC/MS/MS Source parameters 
Gas 1 Gas 2 Temp CE CXP 
40 20 400 49 8 
 
3. Chromatography optimization 
The parameters for chromatography optimization are shown in Table 3.   
Table 3.  Injection and flow rate parameter 
Time (min) Eluent A Eluent B Injection 
Volume 
(µL) 
13 30% 
(0.15 mL/min) 
70% 
(0.35 mL/min) 
20 
 
The flow rate is at a constant (isocratic) ratio of 3:7 for Eluent A and Eluent B, 
respectively.  The retention for each drugs are as followed: 
 DVBL: ~6.0 min. 
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 VBL:  ~ 7.2 min. 
 VRB:  ~10.9 min. 
Vinorelbine was used as the internal standard.  Calibrators were made in methanol 
at the concentration of 100 ng/mL, 10 ng/mL, 5.0 ng/mL, 1.0 ng/mL, and 0.10 ng/mL 
DVBL and VBL together with 50 ng/mL of internal standard in each.  The blanks were 
made up of only 50 ng/mL of internal standard in methanol. 
III. Specific Aim 2: Validate LC/MS/MS Method 
1. Sample preparation 
A stock solution of each drug was provided at the following concentrations:100 
µg/mL VRB , 50 µg/mL DVBL, and 50 µg/mL VBL.  The calibrators were prepared at 
the following concentrations: 100 ng/mL, 10 ng/mL, 1.0 ng/mL, and 0.10 ng/mL.  To 
reach the desired concentration for the standard curve, the calibrators underwent 
dilutions. 
a) Dilutions 
The first dilution was done by pipetting 100 µL of 50 µg/mL DVBL and 50µL of 
100 µg/mL VBL into a 1.0 mL volumetric; deionized water was used to bring to volume.  
This was the standard mixture used for dilutions.  50 µg/mL of VRB was diluted down to 
500 ng/mL with deionized (DI) water.  
200 µL of 5.0 µg/mL of standard mix were diluted with water to make 100 
ng/mL.  1.0 mL of 100 ng/mL standards was diluted down to 10 ng/mL by adding 9.0 mL 
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of water.  The last step was repeated for 1.0 ng/mL and 0.10 ng/mL standards. After each 
dilution step, the samples were vortex for 10 seconds and centrifuged at 3000 rpm for 10 
seconds.  100 L of internal standard was added to 1.0 mL of standards.  All dilutions were 
done at room temperature, ~25°C. 
Table 4.  Dilutions of stock solution 
 Concentration Amount of drug 
added 
Final Volume 
VRB 50 µg/mL   
VRB 1 500 ng/mL 10 µL [VRB] 1.0 mL 
    
DVBL 250 µg/mL   
DVBL 1 5.0 µg/mL 20 µL [DVBL] 1.0 mL 
DVBL 2 500 ng/mL 100 µL [DVBL 1] 1.0 mL 
DVBL 3 200 ng/mL 40 µL [DVBL 1] 1.0 mL 
DVBL 4 50 ng/mL 100 µL [DVBL 2] 1.0 mL 
DVBL 5 20 ng/mL 100 µL [DVBL 3] 1.0 mL 
DVBL 6 5.0 ng/mL 100 µL [DVBL 4] 1.0 mL 
    
VBL 50 µg/mL   
VBL 1 500 ng/mL 10 µL [VBL] 1.0 mL 
VBL 2 200 ng/mL 400 µL [VBL 1] 1.0 mL 
VBL 3 50 ng/mL 100 µL [VBL 1] 1.0 mL 
VBL 4 20 ng/mL 100 µL [VBL 2] 1.0 mL 
VBL 5 5.0 ng/mL 100 µL [VBL 3] 1.0 mL 
 
Table 4 shows the dilution of the stock solutions that were used to make the 
calibrators.  For example, to make 1.0 mL of 200 ng/mL VBL, 400 µL of 500 ng/mL 
VBL ([VBL 1]) was added to a 1.0 mL volumetric test tube and filled up to the line with 
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methanol.  All stock solutions were made up in methanol at room temperature and stored 
in the fridge.   
2. Sensitivity determination  
The stock solutions were then analyzed using the optimized LC/MS/MS method 
from Specific aims 1 and 2.  Following data collection, the data were analyzed to 
determine sensitivity according to the methodology described in Chapter II, section IV.   
IV. Specific Aim 3: Develop a sample preparation strategy to increase 
sensitivity 
The method mentioned above was used to optimize the MS/MS and 
chromatography.  Samples used for optimization was made up in MeOH.  Once the 
sensitivity was determined, the samples underwent LLE or SPE to determine if sensitivity 
had been enhanced. 
1. LLE protocol 
After adding the internal standard to each dilution, 500 µL of organic solvents 
were added for extraction.  The extractions were performed twice for better recovery.  
Three different mixtures of organic solvents were used during this research to see which 
one gave the best recovery.   
Extraction 1 – Hexane: Ethyl acetate [9:1] 
Extraction 2 – Chloroform: Isopropanol [10:1] 
Extraction 3 – Ethyl ether 
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Because the drying state for each extraction can affect the recovery, the samples 
were either dried all the way or partially dried to compare the recovery rate.  Extraction 1 
and Extraction 2 were left to air dry for one to two minutes.  Since ether is a volatile 
organic, the samples from Extraction 3 were left to air dry after extraction.  100 µL of 
Eluent A and Eluent B [3:7] was used to resuspend the samples after drying. 
2. Solid Phase Extraction 
a) Parameters for SPE samples 
Some parameters for LLE stayed the same for SPE with some alterations.  Below 
are modifications of the LC/MS/MS method for SPE samples. 
Eluent A2:  5.0 mM ammonium acetate at pH 3.5 
Eluent B2:  100% HPLC Methanol 
The parameters for chromatography optimization are shown in Table 5. 
Table 5.  Injection and flow rate parameter 
Time (min) Eluent A2 Eluent B2 Injection 
Volume 
(µL) 
15 10% 
(0.075 mL/min) 
90% 
(0.675 mL/min) 
100 
 
The flow rate was set at a constant (isocratic) ratio of 1:9 for Eluent A2 and 
Eluent B2, respectively.  The retention time for each drugs were: 
 DVBL: ~5.0 min. 
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 VBL:  ~ 3.8 min. 
 VRB:  ~4.5 min. 
Vinorelbine was used as the internal standard.  Calibrators were made in methanol 
at concentrations of 5.0 ng/mL, 1.0 ng/mL, 0.50 ng/mL, and 0.10 ng/mL of both DVBL 
and VBL with 10 ng/mL of internal standard in each.  The blanks were made up of 10 
ng/mL of internal standard in methanol. 
b) Dilutions 
 For plasma samples, the lower range of the calibrators was used.   The plasma 
calibrators’ concentrations were 5.0 ng/mL, 1.0 ng/mL, 0.50 ng/mL, and 0.10 ng/mL.  
The internal standard concentration was 10 ng/mL.  Because plasma clogged up the SPE 
column, the samples underwent dilutions prior to solid phase extraction (SPE).  The 
resuspending buffer was 5.0 mM ammonium acetate (pH=3.5), acetonitrile, and methanol 
[50:25:25].   Below is the dilution scheme for plasma solid phase extraction samples: 
Table 6.  Sample dilutions for plasma calibrators. 
Concentration 
(ng/mL) 
VBL DVBL VRB Plasma (µL] 
10 10 µL [VBL 1] 10 µL [DVBL 2] 10 µL [VRB 1] 480 
5 12.5 µL [VBL 2] 12.5 µL [DVBL 
3] 
10 µL [VRB 1] 475 
1 10 µL [VBL 3] 10 µL [DVBL 4] 10 µL [VRB 1] 480 
0.5 12.5 µL [VBL 4] 12.5 µL [DVBL 
5] 
10 µL [VRB 1] 475 
0.1 10 µL [VBL 5] 10 µL [DVBL 6] 10 µL [VRB 1] 480 
Blank 0 0 10 µL [VRB 1] 480 (+ 20 µL MeOH) 
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Table 6 shows the dilution for each calibrator using the corresponding stock 
solutions.  Plasma was aliquoted into microcentrifuge tubes in the amount listed in Table 
6.  10 µL of 500 ng/mL VRB was added to each calibrator as the internal standard.  The 
number in the brackets corresponds to the stock solution number in Table 4.  For 
example, 10 µL of 500 ng/mL VBL ([VBL 1]), 500 ng/mL DVBL ([DVBL 2]) and 500 
ng/mL VRB ([VRB 1]) was added to 480 µL of plasma to make up the 10 ng/mL 
calibrator.  After the addition of the drugs into the microcentrifuge tubes containing 
plasma, the samples were vortexed and centrifuged (3000 rpm) for 10 seconds.  To dilute 
the plasma, 490 mL of deionized (DI) water was added to each tube.  The samples were 
mixed by drawing the solution up and down inside a pipettor.  All dilutions were done 
under a vacuum hood and at room temperature. 
c) SPE protocol 
For solid phase extraction (SPE), an Oasis HLB Cartridge (1.0 mL) (Waters Corporation, 
Milford, MA) was used.  The column was conditioned with 1.0 mL of methanol, then 1.0 
mL of DI water.  The samples were loaded onto the column.  After the samples were 
drawn through the column, 2.0 mL of DI water was used to wash the cartridge.  The 
column was dried under vacuum for 30 minutes.  The waste and test tube were discarded.  
The samples were eluted by adding 2.0 mL of methanol and collected in new test tubes.  
The cartridges were dried down completely (~5.0 minutes). 125 µL of 5.0 mM 
ammonium acetate (pH=3.5), acetonitrile, and methanol [50:25:25] was used as the 
resuspending buffer. 
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V. Specific Aim 4: Validate most sensitive method 
Method validation included four calculations: sensitivity, selectivity, precision, 
and accuracy.  The goal of this research was to reach an LLOQ of less than 1.0 ng/mL; 
therefore, sensitivity was the deciding factor if a method was sensitive enough for 
analysis.  Until the LLOQ reaches a concentration lower than 1.0 ng/mL, selectivity, 
precision and accuracy will not be analyzed.  The calculations for method validation were 
determined in the following order: sensitivity, selectivity, precision, and accuracy. 
1. Sensitivity 
The sensitivity was determined by the LOD and LLOQ values.  A standard curve 
was generated and was used in calculating the LOD and LLOQ.  Equation 1 and Equation 
2 were used to determine the LOD and LLOQ for VBL and DVBL. 
2. Selectivity 
Selectivity was determined by calculating for matrix effects.  For the interest of 
this research, three different equations were used to calculate for matrix effects.  Equation 
5, Equation 6, and Equation 7 were the three main equations used to calculate for matrix 
effects. 
3. Precision 
Precision was calculated by using the mean and standard deviation of the 
calculated concentration from the plasma samples.  Using the calculated quantitation 
ratio, three calibration curves were generated from the three runs within a single day.   
The average y-intercept and slope was determined and used in calculating for the 
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concentrations of each calibrator based on the curve.  The three new calculated values for 
each calibrator were used in calculating for the average concentration and standard 
deviation.  Equation 3 was used to determine the method precision. 
4. Accuracy 
Accuracy was calculated by using the experimental and true value to determine 
the variability between each run.  Using the calculated quantitation ratio, a calibration 
curve was generated.  Three curves were generated for each drug and the average y-
intercept and slope was calculated.  The two values were used to back calculate for the 
concentration of each calibrator based on the curve.  Those calculated (experimental) 
values were used to determine the variability between each run.  Equation 4 was used to 
analyze the accuracy of the method. 
VI. Specific Aim 5: Application of validated method to canine plasma 
Once the developed method was finalized and validated, it was applied to canine 
plasma.  The extraction protocol was transferred to the collaborating party for application 
to canine plasma, then the extracted canine samples were transferred to this laboratory for 
LC/MS/MS analysis. 
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Chapter IV Results 
I. Specific Aim 1: Developed LC/MS/MS Method 
An LC/MS/MS method was developed as described in the Methods section. 
Figure 4 shows a representative chromatogram from a calibrator generated with this 
method. 
 
Figure 4.  Sample chromatogram of VBL, DVBL, and VRB. 
 
II. Specific Aim 2: Validation of LC/MS/MS Method 
1. LOD and LLOQ for calibrators in methanol only 
Table 7 shows the quantitative ratios for VBL and DVBL on the three runs that 
were done on the same day.  The calibrators were in methanol only, no extractions.  
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These quantitative ratios were used to generate the standard curve, shown in Figure 5 
and Figure 6. 
Table 7.  Quantitative ratios for VBL and DVBL 
VBL a  b c 
10 ng/mL 0.642 0.698 0.678 
5 ng/mL 0.222 0.213 0.213 
1 ng/mL 0.0688 0.0711 0.0698 
0.1 ng/mL 0.00888 0.00725 0.00690 
    
DVBL a  b c 
10 ng/mL 0.586 0.658 0.634 
5 ng/mL 0.210 0.198 0.178 
1 ng/mL 0.0563 0.0652 0.0565 
0.1 ng/mL 0.00551 0.00704  
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Figure 5. Calibration curve for VBL in methanol of three different 
runs. 
 
Figure 5 shows the standard curve for VBL on three different runs.  The 
samples were all done on the same day.  The R2 value determines how well the best-fit 
line matches the data.  As show on the graph, the R2 value for all three lines are greater 
than 0.950.  The mean slope for all three curves is 0.0677 and the SD for the y-
intercepts is 0.00522. 
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Figure 6. Calibration curve for DVBL in methanol of three different 
runs. 
 
 Figure 6 showed the calibration curve for DVBL only.  The runs were all done 
on the same day.  All R2 are higher than 0.938. The average of all three slopes is 0.0621 
and the SD for the y-intercepts is 0.0223. 
Table 8.  LLOQ and LOD for vinblastine and deacetylvinblastine in 
MeOH 
 Vinblastine  
(ng/mL) 
Deacetylvinblastine 
(ng/mL) 
LOD ≈0.25  ≈1.2 
LLOQ ≈0.77 ≈3.6 
 
Table 8 shows the limit of detection and limit of quantitation for both VBL and 
DVBL.  To calculate for the LOD, the mean of the slope and the SD of the y-intercept 
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must be calculated from the standard curve generated from the quantitative ratios. The 
values mentioned above were used to calculate the LOD and LLOQ of VBL and 
DVBL.  The LOD and LLOQ for VBL are 0.254 ng/mL and 0.770 ng/mL, and for 
DVBL are 1.186 ng/mL and 3.595 ng/mL, respectively.  The results show that both 
LLOQ and LOD for VBL are lower than DVBL. 
III. Specific Aim 3:  Developed sample preparation strategy to 
increase sensitivity 
1. Liquid-liquid extraction results 
a) LLE solvents 
As mentioned above, three different LLE solvents were tested.  The first solvent 
was a mixture of hexane and ethyl acetate.  The chromatogram (Figure 7) showed that 
the solvent did not work in extracting the drugs.  The next solvent was a mixture of 
chloroform and isopropanol.  The extraction of VBL and DVBL was successful, 
however, the internal peak was not present (Figure 8).  Note that the intensity of VBL is 
at 100,000 cps.  The last solvent used was ethyl ether.  Figure 9 shows the 
chromatogram of the extraction; notice that all three peaks are present.  However, the 
intensity of VBL is only 19,000 cps. 
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Figure 7.  Intensity versus time chromatogram of hexane: ethyl 
acetate LLE. The standards are at 100 ng/mL with the IS at 50 
ng/mL.  No peaks detected. 
 
 
Figure 8.  Chromatogram of LLE with chloroform: isopropanol 
mixture. The standards are at 100 ng/mL with the IS at 50 ng/mL.  
DVBL is at the RT 4.5 min (first peak), VBL RT is 5.5 min (second 
peak), and no VRB peak. 
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Figure 9.  Chromatogram of ether LLE.  The standards are at 100 
ng/mL with the IS at 50 ng/mL.  DVBL is at the RT 5.9 min (first 
peak), VBL RT is 7.0 min (second peak), and VRB RT is at 10.8 min 
(third peak). 
 
b) Drying methods 
From the results above, chloroform and isopropanol gave the best VBL and 
DVBL recovery.  However, the internal standard peak was missing.  To determine what 
caused the peak disappearance, different methods of drying were tested.  Initially, the 
drying method was to let the samples air dry, which took 1.5 to 2.0 hours.  However, an 
alternative method of drying was used to reduce the drying time.  Nitrogen gas was the 
alternative method and reduced the drying time to about 30 min.  Below are sample 
chromatograms of air drying (Figure 10) versus drying with nitrogen gas (Figure 11).  
Notice that the internal standard peak is not present in Figure 10, but reappears in 
Figure 11. 
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Figure 10.  Chromatogram of air-dried sample. 
 
 
Figure 11.  Chromatogram of drying method with nitrogen gas. 
 
Overall, the best method of LLE was using ether as a solvent because all peaks 
were recovered without any problem of byproducts.  Different drying times were tested 
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for ether also, but the drying time did not affect the overall recovery, presumably due to 
its volatile state.   
c) LLE with plasma 
Since the best LLE method utilized ether, it was applied to plasma samples.  
The results for ether extraction with plasma were not the same as those obtained with 
methanolic standards.  Ether was not able to extract all the proteins in the samples, 
therefore, caused the column in the LC to become clogged and leak.  An alternative 
way to remove the proteins was by using acetonitrile (ACN).  An ACN crash method 
was used and all proteins were successfully removed.  However, along with the 
proteins, the drugs were also removed.  Figure 12 shows the chromatogram of an ACN 
crash.  Notice that nothing was detected, which means that all the drugs were lost 
during the protein crash.  Because LLE did not work with plasma, the second option 
was to use SPE to clean up the samples.   
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Figure 12.  Chromatogram of ACN crash. 
 
2. Solid phase extraction results 
Both LLE and SPE methods were test in sample clean up and preparation and 
the results were compared.  Overall, SPE was the best method for the vinca alkaloids 
because proteins were successfully removed from the samples and no drugs were lost 
during the process.  SPE samples did not clog up the system and cause leaking like LLE 
samples.  Because SPE successfully recovered all drugs and removed unwanted 
compounds, the next step is to determine the LOD and LLOQ.  Below are method 
validation results for SPE. 
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IV. Specific Aim 4: Validation of the most sensitive method 
1. Sensitivity: Calibration curve, LOD, and LLOQ for calibrators 
in plasma 
 
Figure 13.  Calibration curves of pre-SPE VBL.   
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Figure 14.  Calibration curves for neat VBL. 
 
 
Figure 15.  Calibration curves for post-SPE VBL. 
 
Figure 13, Figure 14, and Figure 15 are standard curves for VBL of pre-SPE, 
neat, and post-SPE.  The figures show the linearity of all three curves for each set of 
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calibrators.  Notice that all three curves within a set of samples are very close to each 
other, if not overlapping.  This shows that each sample was replicated successfully with 
little variation.  The correlation coefficients, R2, for every curve in all three figures 
were above 0.997. The calculated mean slope for all three curves in Figure 13 was 
0.0512 and the SD of the y-intercepts was 0.00233.  In Figure 14, the calculated mean 
slope is 0.0638 and the SD is 0.00355.  In Figure 15, the calculated mean slope is 
0.0536 and the SD is 0.000987.   The SD value and the mean slope will be used in 
determining the LOD and LLOQ of VBL. 
 
Figure 16.  Calibration curves of pre-SPE DVBL. 
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Figure 17.  Calibrations curves for neat DVBL. 
 
 
Figure 18.  Calibration curves for post-SPE DVBL. 
   
Figure 16, Figure 17, and Figure 18 are standard curves for DVBL of pre-SPE, 
neat, and post-SPE.  The figures show the linearity of all three curves for each set of 
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calibrators.  Again, notice that all three curves within a set of samples are very close to 
each other, if not overlapping.  This shows that each sample was replicated successfully 
with little variation.  The correlation coefficients, R2, for every curve in all three figures 
are above 0.994.  The mean slope for Figure 16, Figure 17, and Figure 18 is 0.0308, 
0.0296, and 0.160, respectively. The SD of the y-intercepts for Figure 16, Figure 17, 
and Figure 18 is 0.000643, 0.00190, and 0.484, respectively.  The SD value and the 
mean slope will be used in determining the LOD and LLOQ of DVBL. 
 
Table 9. LOD and LLOQ for VBL and DVBL for neat, pre-SPE, 
and post-SPE 
 Neat 
(ng/mL) 
Pre SPE 
(ng/mL) 
Post SPE 
(ng/mL) 
 LOD LLOQ LOD LLOQ LOD LLOQ 
VBL 0.184 0.557 0.150±0.016 0.455±0.047 0.061 0.184 
DVBL 0.212 0.643 0.069±0.003 0.209±0.01 0.160 0.484 
 
 Table 9 shows the LOD and LLOQ for VBL and DVBL for all three different 
methods.  LODs for VBL were 0.184, 0.150, and 0.061 ng/mL for neat, pre-SPE, and 
post-SPE, respectively.  The estimated LODs for DVBL were 0.212, 0.069, and 0.160 
ng/mL for neat, pre-SPE, and post-SPE, respectively.  Estimated VBL LLOQs for the 
three methods were about 0.557, 0.455, and 0.184 ng/mL.  Estimated DVBL LLOQs 
were around 0.643, 0.209, and 0.484 ng/mL.  Since the goal of this research was to 
obtain a LLOQ lower than 1.0 ng/mL, the next steps were to calculate for recovery, 
matrix effects, precision, and accuracy of the method. 
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2. Selectivity 
a) Matrix effect, recovery, and process efficiency 
The calculations for matrix effects were done for only the 5.0 ng/mL calibrators.  
The numbers shown in columns A, B, and C are the peak area of each drug.  As shown 
in the table, each column was assigned a letter corresponding to the letters in Equation 
5, Equation 6, and Equation 7.  To calculate for ME(%), the mean value for column B 
was divided by the mean value in column A for each drug.  For RE(%), the mean value 
in column C was divided by the mean value in column B for each drug.  For PE(%), the 
mean value in column C was divided by the mean value in column A for each drug.  
The results for ME(%) were 65.7%, 76.5%, and 78% for VBL, DVBL, and VRB, 
respectively.  RE(%) results were 65.3%, 72%, and 68.7 for VBL, DVBL, and VRB, 
respectively.  Lastly, the values for PE(%) were 42.9%, 55.1%, and 53.6% for VBL, 
DVBL, and VRB, respectively.  The calculations and results are shown on Table 10. 
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Table 10.  ME, RE, and PE calculations for 5.0 ng/mL VBL, DVBL, 
and VRB in neat, post-SPE, and pre-SPE 
 A B C   
 VBL Neat VBL Post VBL Pre   
1 8.91E+05 5.47E+05 2.86E+05 ME (%) 65.7 
2 8.39E+05 5.34E+05 4.04E+05 RE (%) 65.3 
3 7.99E+05 5.81E+05 3.96E+05 PE (%) 42.9 
Mean 8.43E+05 5.54E+05 3.62E+05   
% Avg. 
recovery 
42.9     
      
 DVBL Neat DVBL Post DVBL Pre   
1 3.88E+05 3.14E+05 1.58E+05 ME (%)  76.5 
2 3.90E+05 2.74E+05 2.43E+05 RE (%)  72.0 
3 3.77E+05 2.95E+05 2.35E+05 PE (%)  55.1 
Mean 3.85E+05 2.94E+05 2.12E+05   
% Avg. 
recovery 
55.1     
      
 VRB Neat VRB Post VRB Pre   
1 2.57E+06 2.03E+06 1.08E+06 ME (%)  78.0 
2 2.70E+06 2.08E+06 1.49E+06 RE (%)  68.7 
3 2.83E+06 2.21E+06 1.77E+06 PE (%)  53.6 
Mean 2.70E+06 2.11E+06 1.45E+06   
% Avg. 
recovery 
53.6     
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3. Precision 
Table 11.  Precision calculations for VBL and DVBL from pre-SPE 
samples 
VBL 
 Pre SPE a Pre SPE b Pre SPE c Mean SD Precision  
5 ng/mL 5.021 4.993 5.007 5.007 0.014 0.27% 
1 ng/mL 0.922 1.076 1.037 1.011 0.080 7.91% 
0.5 
ng/mL 
0.440 0.402 0.394 0.412 0.024 5.85% 
0.1 
ng/mL 
0.221 0.127 0.170 0.173 0.047 27.41% 
Average     0.041 10.36% 
DVBL 
 Pre SPE a Pre SPE b Pre SPE c Mean SD Precision 
5 5.042 5.026 5.039 5.036 0.009 0.17% 
1 0.753 0.863 0.799 0.805 0.055 6.89% 
0.5 0.545 0.484 0.526 0.518 0.031 5.99% 
0.1 0.261 0.229 0.245 0.245 0.016 6.52% 
Average     0.028 4.89% 
 
Table 11 shows the precision results for VBL and DVBL.  Precision was 
calculated by taking the calculated SD and dividing by the mean of the three pre-SPE 
runs for each calibrator.  As shown on the table, from 5.0 ng/mL to 0.50 ng/mL VBL 
the precision percentages were under 10%, but at 0.10 ng/mL the precision was 
27.41%.  The precision percentage for DVBL ranges from 6.89% - 0.17%. 
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4. Accuracy 
 
Table 12. Vinblastine and Deacetylvinblastine Accuracy 
Calculations 
 Calculated concentration (ng/mL)   
VBL Pre-SPE a Pre-SPE 
b 
Pre-
SPE c 
Mean calc. 
conc. 
Accuracy (% 
error) 
5 ng/mL 5.021 4.993 5.007 5.007 0.14 
1 ng/mL 0.922 1.076 1.038 1.011 1.14 
0.5 
ng/mL 
0.440 0.402 0.394 0.412 -17.58 
0.1 
ng/mL 
0.221 0.127 0.170 0.173 72.70 
      
 Calculated concentration (ng/mL)   
DVBL Pre-SPE a Pre-SPE 
b 
Pre-
SPE c 
Mean calc. 
conc. 
Accuracy (% 
error) 
5 ng/mL 5.042 5.026 5.039 5.036 0.71 
1 ng/mL 0.753 0.863 0.799 0.805 -19.50 
0.5 
ng/mL 
0.545 0.484 0.526 0.518 3.65 
0.1 
ng/mL 
0.261 0.229 0.245 0.245 145.45 
 
Table 12 shows the calculation for the accuracy of the data.  Accuracies were 
calculated by dividing the calculated mean concentration (n=3) by the true value of 
each calibrator in the pre-SPE batch.  As shown on the table, the 0.10 ng/mL VBL 
calibrator has the highest % error at 72.70%.  Both 5.0 ng/mL and 1.0 ng/mL have the 
lowest accuracy error at 0.14% and 1.14%, respectively.  The accuracy of the 0.50 
ng/mL VBL was -17.58%.  For DVBL, 5.0 ng/mL and 0.50 ng/mL have the lowest 
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accuracy percentage at 0.71% and 3.65%, respectively.  The 1.0 ng/mL accuracy value 
is at -19.50%, while the 0.10 ng/mL DVBL have the highest percent error at 145.45%. 
V. Specific Aim 5: Application of validated method to canine 
plasma samples 
 Clinical application was made to samples previously collected from a canine 
named Tyson.  Tyson had been previously treated with vinblastine and plasma samples 
were taken from him in intervals from 0 to 24 hours.  The calibrators ranged from 0.125 
ng/mL to 20 ng/mL.  The calibrators and canine samples for this analysis were prepared 
by collaborators at the OSU CVHS.   
Table 13.  VBL calibrators quantitation ratios of low and high end. 
Low End High End 
Sample (ng/mL) Quant. Ratio Sample (ng/mL) Quant. Ratio 
0.125 0.0022 2 0.0483 
0.25 0.0033 5 0.1732 
0.5 0.0083 10 0.4048 
1 0.0250 20 0.8604 
2 0.0483   
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Table 14.  DVBL calibrators concentration and quantitation ratios. 
Sample (ng/mL) Quant. Ratio 
0.125 0.0014 
0.25 0.0023 
0.5 0.0049 
1 0.0168 
2 0.0271 
 
Table 13 and Table 14 show the calibrator concentrations for VBL and DVBL, 
respectively, that were used in generating the standard curve.  The ID ratios were 
calculated for each calibrator and all were within 20% of expected values for both VBL 
and DVBL, which mean none of the calibrators were excluded.  Two standard curves 
were generated for VBL, low and high end, because a combined curve caused skewed 
data points.  Both tables show the calculated quantitation ratios. 
 
59 
 
 
Figure 19.  Low end of VBL standard curve. 
 
 
Figure 20.  High end of VBL standard curve 
 
Figure 19 and Figure 20 shown above is the lower and higher end of VBL 
calibrators, respectively.  The axis of the graph was quantitative ratio versus 
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concentration.  As shown in the figures, both curves were linear and the R2 values were 
above 0.990.  
 
Figure 21.  Standard curve of DVBL. 
 
Figure 21 shows the standard curve for DVBL.  This curve was not divided into 
high and low end since the calibrators for DVBL only range from 0.125 ng/mL to 2 
ng/mL and there was no high end.  The R2 value was above 0.970 was not quite as good 
as the VBL standard curve but sufficient for quality control purposes and valid in 
determining the unknown concentrations. 
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Figure 22.  Time curve of Tyson VBL and DVBL level over a 24-
hour period. 
 
 
Figure 23.  Time curve for Tyson’s plasma samples after 3 hours.  
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 Figure 22 is a concentration versus time graph that shows the concentration of 
VBL decreasing over time.  The calculated concentration for each unknown was 
determined by using the standard curves above (Figure 19, Figure 20, and Figure 21).  
As shown on the graph, VBL decreased very rapidly within an hour.  Figure 23 is a 
close up look at the relation between VBL and DVBL level after 3 hours.  The graph 
showed that VBL was slowly decreasing as DVBL was increasing.  The graphs showed 
that as VBL was breaking down, DVBL was being produced.
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Chapter V Discussion 
I. Specific Aim 1 & 2:  Development and validation of LC/MS/MS 
method 
1. ESI vs. APCI 
As part of method development, both ESI and APCI were used to determine 
which ionization method was the best for vinblastine detection.  Both ESI and APCI 
detected VBL, DVBL, and VRB, but APCI seem to have higher sensitivity than ESI.  
Table 15 shows the LOD and LLOQ comparison between ESI and APCI mode.  As 
shown on Table 15, the LODs and LLOQs for VBL are lower when APCI mode was 
used.  VBL LOD and LLOQ were about 0.0246 ng/mL and 0.0821 ng/mL in APCI mode 
versus 0.0309 ng/mL and 0.103 ng/mL for ESI mode, respectively.  For DVBL, ESI 
mode seems to be the better choice with a LOD of 0.202 ng/mL and LLOQ of 0.672 
ng/mL.  DVBL in APCI mode has a higher LOD and LLOQ of 0.307 ng/mL and 1.02 
ng/mL, respectively.  When comparing the APCI and ESI chromatograms, the noise level 
was lower and the peaks had better resolution when using APCI. 
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Table 15.  VBL and DVBL LOD and LLOQ comparison between ESI 
and APCI 
 ESI APCI 
 LOD (ng/mL) LLOQ (ng/mL) LOD (ng/mL) LLOQ (ng/mL) 
VBL ≈0.0309 ≈0.103 ≈0.0246 ≈0.0821 
DVBL ≈0.202 ≈0.672 ≈0.307 ≈1.02 
 
The results above were only used to determine which mode of ionization would be 
optimal for the compound of interest.  Even though the LLOQ under APCI was very low, 
the value will change depending on the specimen.  In reality, unknown samples will come 
in specimens (plasma, urine, etc.) that will need to be purified, which can affect sample 
recovery.  This research was developed for samples in plasma; therefore, preparation 
procedures for other matrices may need to be generated.  In this case, the LC/MS/MS was 
tuned and optimized successfully for vinca alkaloids in APCI mode. 
II. Specific Aim 3:  Develop a sample preparation strategy to 
increase sensitivity 
1. Liquid-liquid extraction 
During the whole method development for this project, LC/MS/MS and extraction 
methods were changed many times in order to reach the desired results.  The first 
attempted extractions were liquid-liquid extraction using three different solvents.  The 
first solvent used was a mixture hexane and ethyl acetate, and none of the drugs were 
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recovered (Figure 7).  The second solvent was a mixture of chloroform and isopropanol, 
which showed higher recovery, however, the internal standard peak disappeared (Figure 
8).  Chloroform was the most commonly used solvent for LLE involving vinca alkaloids, 
and none of the studies reported any problems with chloroform.  Therefore, the 
hypothesis was that VRB interacted with isopropanol, which caused byproducts.  A full 
scan of the samples were done, which showed other related materials by m/z in the 
solution.  However, the identity of the byproducts was not determined due to time 
constraints.  Because of the byproducts associated with isopropanol, ether was attempted 
as a third solvent (Figure 9).  The LLOQ for this method was 0.682 ng/mL and 0.990 
ng/mL for VBL and DVBL, respectively.  Since ether gave the best overall detection, the 
solvent was tried with plasma samples.   
When ether was used on plasma as opposed to methanolic standards, a new 
problem arose.  The HPLC column got clogged, which caused leaking due to pressure 
build up on the system.  Even though ether successfully extracted the drugs, enough 
proteins were still present in the samples to cause LC failure.  Therefore, another method 
was developed using acetonitrile to crash out the proteins before LLE.  Even though the 
ACN crash eliminated the clogging problem by removing the proteins, all of the drugs 
were lost during this step (Figure 12).  As available references indicate that the fraction of 
drug that is protein bound is 75% (Baselt, 2008), the acetonitrile crash likely caused the 
vinca alkaloids to be lost from the extraction along with precipitated proteins.  
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a) Drying methods 
Two different drying methods were tested to determine which one gave the best 
recovery.  When the VRB peak disappeared in the chloroform:isopropanol extraction, a 
factor that was taken into consideration was the drying time.  The initial hypothesis was 
that isopropanol was reacting with VRB, which formed byproducts.  Therefore, it was felt 
that if the time of exposure to the isopropanol was minimized, there would be less time 
for reactions to occur and this would result in better recovery.  The original drying time at 
room temperature was greater than two hours, so another method of drying was used, 
which used nitrogen gas to speed up the drying time.  By using nitrogen, the drying time 
was decreased to less than one hour and the IS peak returned with the nitrogen gas 
modification (Figure 11). 
Even though nitrogen gas worked in eliminating the problem of byproducts, to 
totally eliminate the problem in the future, a new method was created.  Since LLE caused 
many issues and did not give optimal results, SPE was developed to test for sensitivity.  
To eliminate any drying variables that could affect the results, both drying at room 
temperature and with nitrogen gas was used after SPE.  The overall results showed that 
the drying methods did not affect sample recovery in the SPE method.  This result 
confirms the hypothesis of vinca alkaloid loss through reactivity with isopropanol during 
LLE.   
2. Solid phase extraction 
Because LLE was unsuccessful due to column clogging, low recovery, and peak 
disappearance, SPE was attempted.  Two different SPE methods were developed, 
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although results from the first SPE method did not yield optimal recovery.  The LOD and 
LLOQ for VBL were 0.348 ng/mL and 1.05 ng/mL, respectively.  The second SPE 
method was a modification of the first method to increase sensitivity.  The change from a 
low percentage methanol wash to a water wash served to leave more vinca alkaloids on 
the SPE column prior to elution, preventing unnecessary losses and therefore increasing 
sensitivity.  The increase in column drying time served to ensure that there were no voids 
due to immiscible liquids when the vinca alkaloids were eluted from the SPE column, 
increasing efficiency of extraction.  Combined, the changes to the method did increase 
the recovery rate and the LOD and LLOQ of VBL for the new method were 0.119 ng/mL 
and 0.361 ng/mL, respectively.   
III. Specific Aim 4:  Validation of the most sensitive method 
1. Precision 
The results for VBL showed that the precision is within 10% from 0.50 ng/mL to 
5.0 ng/mL, but at 0.10 ng/mL the error was over 20%, while all DVBL precision results 
were under 10%.  In general, working at lower concentrations causes the method to be 
more sensitive to variations in the amount of analyte injected on the LC column, since 
any changes are a larger proportion of the instrument signal.  Variations could be caused 
by pipetting variables with internal standard or sample volumes.  In any case, the 
concentrations that exhibited precision outside the normally accepted value of 20% were 
actually below the calculated method lower limit of quantitation.  Therefore, the lack of 
precision at the low concentration is actually an encouraging result since it validates the 
approach used to calculate the LLOQ and the LOD.   
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2. Accuracy 
The accuracy for DVBL and VBL were close to 100%±20% from 0.50 ng/mL to 
5.0 ng/mL.  However, at 0.10 ng/mL the accuracy error was over 20%.  Accuracy is like 
precision in that at lower concentrations small changes can result in a large variation in 
the result.  As in the case with precision, the only accuracy value that was out of the 
normally accepted 20% was below the calculated LLOQ.  Therefore all values obtained 
with the method were within normally accepted quality control parameters.  
3. Sensitivity 
The lowest LOD and LLOQ that could be detected with the new method were 
0.150 ng/mL and 0.455 ng/mL for VBL, and 0.069 ng/mL and 0.209 ng/mL for DVBL, 
respectively.  As discussed above, the precision and accuracy at these calculated values 
were within the normally acceptable quality assurance criteria.  These values compare 
favorably with prior LC/MS/MS studies on vincristine.  (Corona et al., 2008)  While 
certain LC/F methods are capable of producing similar results for VBL, they are not as 
selective as LC/MS/MS and their sensitivities to DVBL are low.  (Vendrig, Teeuwsen, & 
Holthuis, 1988) 
4. Selectivity 
a) Matrix effects and recoveries 
The matrix effects for the developed method for VBL, DVBL, and VRB were 
65.7%, 76.5%, and 78%, respectively.  The equation for calculating ME was to divide 
post-SPE by neat samples.  ME was calculating for the matrix effect of the process 
starting from when the analytes were eluted from the column.  The matrix effect for VBL 
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was 65.7%, which meant that 34.3% of the analytes were suppressed.   23.5% of DVBL 
were being suppressed and 22% for VRB.  There are several possible mechanisms of 
suppression.  One mode purports that there is a limited amount of material that can be 
ionized as it travels into the source.  Therefore, if multiple compounds emit 
simultaneously, compounds that ionize easily might be more likely to ionize than those 
that do not ionize with high efficiency.  Another mode might be through a co-eluting 
compound binding to the analytes, which then prevent them from ionizing and entering 
the MS.  While the mechanism of suppression in this case is not known, it is apparent that 
suppression is occurring.  As the suppression is directly related to the matrix being 
extracted, plasma, this method is only valid for use in plasma and the experiments would 
need to be performed again in a different matrix to determine if suppression was still 
occurring.  While minimal suppression would be ideal, there is no current value at which 
a method is disqualified due to its presence.  (Matuszewski et al., 2003)  
The equation for RE was calculated by taking the pre-SPE results and dividing by 
the post-SPE results.  RE was calculating for the recovery of the analytes between the 
extractions to the drying process.  PE was calculating the overall yield from the first step 
to the last step of the whole process.   From the results above, 65.3% (RE) of what was 
initially there was recovered after extractions, which means 34.7% was lost on the 
column.  The end results gave the total yield of 42.9% (PE), which means the process 
was not very efficient.  However, even with the loss of efficiency, the method was more 
sensitive and selective than previous methods. 
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IV. Specific Aim 5:  Application of validated method to canine plasma 
samples 
The developed LC/MS/MS and extraction method was successfully applied to 
canine plasma.  The graphs for Tyson showed that after three hours, as VBL was 
decreasing, DVBL was increasing.  This meant that after 3 hours of injecting the drugs 
into the canine, VBL was broken down into DVBL, the metabolite.  The goal of a 
pharmacokinetic study is to determine the absorption, distribution, metabolism and 
elimination of the drug in the system after administration, also known as ADME.  The 
results suggest that VBL decreases rapidly within the first hour after administration, and 
the metabolite, DVBL, can be detected after three hours.  If the only mode of metabolism 
and excretion were through the production and elimination of DVBL, then the amount of 
VBL lost should equal the amount of DVBL being made.  However, VBL can be broken 
down into different metabolites or eliminated from the body in its original form, so the 
amount of DVBL produced is less than the decrease in VBL concentration.  This research 
is only looking at canine plasma and not urine, so the amount of parent VBL being 
eliminated through urine is not known.   
This method was applied to one canine subject, but the collaborator goals in the 
OSU CVHS are to apply it to samples from animals of various sizes, determine the 
appropriate pharmacokinetic model for the animals, and use the developed 
pharmacokinetic model for more accurate chemotherapy dosing.  This method is the first 
step towards these greater goals. 
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V. Conclusions 
A sensitive and selective SPE LC/MS/MS method was develop that can detect 
and quantitate vinblastine and its metabolite, deacetylvinblastine, at a concentration lower 
than 1.0 ng/mL.  LLE, protein precipitation, and SPE were explored and the end results 
showed that SPE was the best extraction method.  The accuracy and precision of the 
calibrators were acceptable in the linear range of the method.  This method was 
successfully applied to samples from a canine subject, and will be used on more subjects 
in the future.   
VI. Future Work 
Due to time constraints, this newly developed method was only applied to one 
dog, but there are several samples from canine subjects awaiting analysis.  Even though 
the newly developed SPE LC/MS/MS method was successful in detecting and 
quantitating low concentrations of VBL and DVBL, more improvements need to be 
explored to increase process efficiency.  Since more than half of the samples were lost 
due to matrix and column effects, an alternative solvent and/or column could be used to 
increase recovery and decrease matrix effects.  Another area that needs to be explored is 
the unknown peak eluting at 2.0 minutes on the chromatogram from extracted calibrators 
and samples.  Again, because of the time constraints, the unknown peak was not 
identified, but future work might attempt to identify the unknown peak.   
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Scope and Method of Study: - The purpose of this study was to develop and 
validate an analytical method for vinblastine (VBL) and deacetylvinblastine 
(DVBL) using liquid chromatography tandem mass spectrometry (LC/MS/MS).  
The goal of the study was to develop a method that is sensitive enough to 
quantitate less than 1.0 ng/mL in plasma.  The first step in method development 
was to optimize the LC/MS/MS by tuning the ion path and optimizing source 
parameters and chromatography.  After development of the LC/MS/MS method, a 
solid phase extraction sample preparation method was developed and optimized to 
increase sensitivity.  Method validation was carried out through determination of 
the sensitivity, selectivity, precision, and accuracy of the method.  This method 
was then applied to canine plasma samples. 
 
Findings and Conclusions:  The LC/MS/MS method was successfully developed 
for detection of vinblastine and desacetylvinblastine with vinorelbine as the 
internal standard.  The LC method utilized isocratic flow rate with atmospheric 
chemical ionization (APCI) and three ions per analyte in multiple reaction 
monitoring (MRM) mode.  Calibrators in methanol resulted in a LLOQ for 
vinblastine of approximately 0.77 ng/mL and of deacetylvinblastine at 
approximately 3.6 ng/mL.  The LLOQ for plasma samples after SPE was 
0.445±0.047 for VBL and 0.209±0.01 ng/mL for DVBL.  The developed method 
for plasma extracted with SPE and analyzed via LC/MS/MS was validated and 
successfully applied to canine plasma samples.   
